Atrial Fibrillation Risk Genotype
The Atrial Fibrillation Risk Genotype test profiles inherited single-nucleotide polymorphisms at 4q25, 16q22, and additional loci, synthesising them into a polygenic risk score that stratifies baseline genetic susceptibility to AF. It is an adjunct to clinical risk assessment, enhancing shared decision-making about anticoagulation, monitoring, and lifestyle modification, though it is not…
3
Biomarkers
Blood (whole blood)
Sample
10–14 business days
Turnaround
No
Fasting
What is the AF Risk Genotype test?
The Atrial Fibrillation Risk Genotype test interrogates inherited single-nucleotide polymorphisms at chromosomal loci robustly associated with AF susceptibility—principally 4q25 and 16q22—and synthesises them into a polygenic risk score. It is an adjunct to clinical risk stratification, ordered to quantify an individual's inherited predisposition when family history is notable, when the practitioner and patient seek to inform shared decision-making about anticoagulation or rhythm surveillance in borderline scenarios, or when optimising preventive strategies in patients with multiple modifiable risk factors but no overt structural heart disease. Genetic risk for AF is continuous, population-relative, and probabilistic rather than deterministic; the test result does not diagnose disease, does not predict the timing of an incident event, and does not replace electrocardiographic monitoring or clinical risk scores. Its primary utility lies in refining pre-test probability, enhancing patient motivation for blood-pressure control and weight loss, and supporting nuanced discussions about the interplay of inherited and acquired factors in a common, heritable arrhythmia.
What does the AF Risk Genotype test measure?
The 4q25 locus, situated near the PITX2 and ENPEP genes, harbours common single-nucleotide polymorphisms that modulate cardiac electrical development and left-atrial gene expression. PITX2 is a transcription factor critical to left–right cardiac asymmetry and pulmonary-vein myocardial sleeve differentiation during embryogenesis; variant alleles at rs2200733, rs10033464, and other linked SNPs alter its regulation, thereby influencing susceptibility to re-entrant circuits that trigger atrial fibrillation. These are inherited trait markers rather than acquired mutations, present from conception and stable over the lifespan.
Genome-wide association studies have identified 4q25 variants as the strongest common genetic predictors of atrial fibrillation, conferring approximately 1.5–2× risk per copy of the high-risk allele in European-ancestry populations. The genotype does not cause AF in isolation but interacts with age, hypertension, structural heart disease, and other environmental factors to determine an individual's cumulative risk. Knowledge of elevated genetic susceptibility may inform risk stratification, enhance patient engagement in lifestyle modification, and guide decisions about anticoagulation thresholds and monitoring intensity, though it does not substitute for clinical risk scores.
The 16q22 region contains the ZFHX3 gene, encoding a zinc-finger homeobox transcription factor expressed in atrial myocytes and involved in regulation of cardiac ion channels and structural remodelling. Polymorphisms at rs7193343 and linked SNPs modulate ZFHX3 expression and are independently associated with AF susceptibility, likely through effects on atrial electrical properties and fibrosis pathways.
16q22 variants represent a second independent genetic locus contributing to AF risk, with effect sizes slightly smaller than those at 4q25 but additive when both loci carry risk alleles. The combination of multiple risk loci improves discrimination of individuals at the tails of the genetic-risk distribution.
The polygenic risk score integrates genotypes at 4q25, 16q22, and additional validated loci—each contributing small independent effects—into a single composite measure. It reflects the cumulative burden of inherited common variants that collectively influence atrial electrical and structural substrate, independent of acquired clinical risk factors.
A polygenic risk score stratifies baseline genetic susceptibility and may identify individuals who would benefit from earlier or more intensive risk-factor modification, particularly when combined with clinical scores such as CHARGE-AF or CHA₂DS₂-VASc. It does not predict imminent AF onset, is not diagnostic, and must be integrated with clinical risk factors, imaging, and longitudinal monitoring.
Why is the AF Risk Genotype test ordered?
- Patients with a strong family history of atrial fibrillation (multiple first-degree relatives affected at younger ages) who wish to understand their inherited risk
- Individuals with borderline CHA₂DS₂-VASc scores in whom quantification of genetic susceptibility may influence anticoagulation or monitoring decisions
- Younger patients with unexplained paroxysmal palpitations and structurally normal hearts, where elevated genetic risk would lower the threshold for extended rhythm monitoring
- Patients with multiple modifiable risk factors (obesity, hypertension, obstructive sleep apnoea) who may benefit from personalised risk communication to enhance adherence to lifestyle interventions
- Individuals enrolled in preventive cardiology or executive-health programmes seeking comprehensive cardiovascular risk profiling beyond traditional scores
- Patients requesting genetic insight after an immediate family member has been diagnosed with AF or experienced a stroke attributed to undiagnosed arrhythmia
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
10–14 business days
Collection notes
Phlebotomy at the processing laboratory site; whole blood collected in EDTA (purple-top) tube for DNA extraction. No dietary preparation required. Sample must be refrigerated if not processed promptly; avoid freeze–thaw cycles.
Specimen requirements
Minimum 3–5 mL whole blood in EDTA anticoagulant. DNA extraction and genotyping performed by Boston Heart Diagnostics proprietary platform. Label specimen clearly; confirm patient identity and ensure informed consent is documented.
What can affect AF Risk Genotype results?
Effect sizes and allele frequencies differ across ancestral groups; most validation cohorts are European-ancestry, so risk estimates may be less accurate in individuals of African, East Asian, or admixed ancestry.
Different genotyping platforms interrogate different numbers of loci and apply distinct weighting algorithms; polygenic scores are not interchangeable between laboratories or assays.
Degraded or low-yield whole-blood samples may result in no-call genotypes, reducing the completeness of the polygenic score; fresh or EDTA-preserved blood is preferred.
Patients may misinterpret genetic risk as deterministic or may experience anxiety; results should be accompanied by pre- and post-test counselling to contextualise findings within clinical risk.
Genetic susceptibility is expressed differently at different ages and in the presence or absence of hypertension, heart failure, or valvular disease; the polygenic score is a baseline trait and does not change with incident comorbidity.
What do AF Risk Genotype results mean?
Elevated
Individuals in the upper quintile or decile of the polygenic risk distribution carry approximately 2–3× the AF risk of those at the population median, driven by high-risk alleles at 4q25, 16q22, or other loci. This is a baseline inherited susceptibility, not a near-term prediction; absolute risk still depends on age, blood pressure, structural heart disease, and other acquired factors. Elevated genetic risk warrants enhanced attention to modifiable factors—hypertension control, weight optimisation, alcohol moderation, and obstructive sleep apnoea treatment—and may lower the threshold for extended rhythm monitoring in the setting of palpitations or cryptogenic stroke. It does not by itself mandate anticoagulation or rhythm therapy.
Normal
Individuals near the population median carry an average inherited susceptibility; their lifetime AF risk will be determined predominantly by clinical factors—age, hypertension, heart failure, valvular disease, diabetes, and lifestyle. A median polygenic score neither elevates nor lowers clinical suspicion and should not alter standard care pathways.
Reduced
Individuals in the lower quintile have inherited fewer risk alleles and carry approximately half the AF risk of the population median, though they are not immune; acquired factors can still precipitate AF. A low polygenic score may provide reassurance in the setting of a family history that proves to be environmentally rather than genetically driven, but it does not obviate the need for clinical risk assessment or monitoring when symptoms or structural heart disease are present.
Note: Genetic risk is probabilistic, population-relative, and does not predict when or whether an individual will develop AF. The test is not diagnostic, does not replace rhythm monitoring, and should not be the sole basis for anticoagulation or invasive therapy. Effect sizes and validation are strongest in European-ancestry cohorts; accuracy is lower in other ancestries. Informed consent, genetic counselling, and attention to data privacy are essential. Results are a stable trait and do not require serial retesting.
Frequently asked questions
It profiles inherited single-nucleotide polymorphisms at chromosomal loci associated with AF—principally 4q25 and 16q22—and integrates them into a polygenic risk score that reflects baseline genetic susceptibility to atrial fibrillation.
How to access the AF Risk Genotype test
The AF Risk Genotype reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Lubitz SA, et al. Genetic risk prediction of atrial fibrillation. Circulation. (2017)
- Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. (2018)
- Christophersen IE, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. (2017)
- January CT, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. (2019)
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
hs-CRP
The high-sensitivity C-reactive protein (hs-CRP) test measures low concentrations of C-reactive protein in serum to assess chronic, low-grade systemic inflammation. It is used to refine cardiovascular risk stratification alongside lipid measures, with values below 1.0 mg/L indicating low risk and above 3.0 mg/L indicating high risk. Testing must be performed away from acute infection or injury.
metabolic diabetes
CMP
The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.